Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer by Rizzoli, René
Annals of Oncology 15: 700–701, 2004Editorial DOI: 10.1093/annonc/mdh195
© 2004 European Society for Medical Oncology
Bisphosphonates and reduction of skeletal 
events in patients with bone metastatic breast 
cancer
Formerly called diphosphonates, bisphosphonates have been used
as water softeners since the second half of the nineteenth century.
Their role in bone and mineral metabolism was recognized about
35 years ago with the pioneering research of Herbert Fleisch in
Switzerland [1, 2]. More recently, bisphosphonates have become
the first choice for standard care in the management of bone
diseases associated with hyper-resorption, such as Paget’s bone
disease, hypercalcemia of malignancies, osteoporosis (both idio-
pathic and secondary), disuse, and prosthesis or implant loosen-
ing. Their consistent and large efficacy in preventing skeletal
events associated with bone metastases is a situation in which
bisphosphonate treatment has fundamentally modified the course
of the disease complications, and hence has contributed to
decreased bone pain, skeletal morbidity and to a markedly
improved quality of life for numerous patients [3, 4]. Bone meta-
stases may be present in more than three-quarters of patients with
breast cancer. A recent systematic review [4] indicates that
bisphosphonate therapy of patients with metastatic breast cancer
is associated with: a reduction of non-vertebral fracture [odds ratio
(OR) 0.80], combined fractures (OR 0.75), a need for radiotherapy
(OR 0.65) or for orthopedic surgery (OR 0.59), and episodes of
hypercalcemia (OR 0.43). For metastatic bone diseases, the benefit
of bisphosphonates on radiotherapy and hypercalcemia are
observed as early as at 6 months, whereas the need for orthopedic
surgery is significantly decreased by 24 months. These data
clearly illustrate the magnitude of the benefits of bisphosphonate
therapy on bone-related morbidity (20% to >50% reduction in
skeletal events), and the expected time frame of these benefits. In
addition, bisphosphonate therapy significantly increases the time
to the first skeletal-related event, but bisphosphonates do not
appear to affect overall survival, with the possible exception of
some patients subgroups. Their efficacy in reducing breast cancer
morbidity has been demonstrated in well-conducted randomized,
placebo-controlled trials, with the intravenous administration of
pamidronate, zoledronate or ibandronate [5–8], or with clodronate
given orally [9, 10]. Oral bisphosphonates appear to be associated
with lower ORs for vertebral and non-vertebral fracture risk,
somewhat equivalent to the intravenous treatment.
The phosphate–carbon–phosphate structure of bisphosphonates
makes them resistant to hydrolytic enzymes and confers a preferen-
tial and selective tropism for bone mineral. Thus, they specifically
accumulate on the surface of bone. This characteristic represents
the basis of bone scintigraphy with technetium-labeled phos-
phonates. The duration of the effects of bisphosphonate may be
related to their binding affinity for hydroxyapatite. Those com-
pounds with a stronger binding appear to have a longer duration of
action. Once taken up by the bone osteoclasts during the course of
bone resorption, bisphosphonates both reduce osteoclast activity
and promote their apoptosis. The molecular mechanism of action
involves either the incorporation of bisphosphonates into inactive
ATP analogs (this mechanism involves clodronate, etidronate and
tiludronate) or the inhibition of the enzyme farnesyl synthase, an
enzyme in the cholesterol synthesis pathway (for nitrogen-
containing bisphosphonates). The product of this enzymatic
reaction, farnesyl-pyrophosphate, or the next product, the lipid
geranylgeranyl-pyrophosphate, bind to Ras, Rho and other
GTPases, through a reaction called prenylation, which is required
for cytoskeletal organization and vesicular traffic within the
osteoclasts. Decreased prenylated proteins lead to osteoclast
inactivation [11, 12]. Bisphosphonates may also exert direct anti-
tumor activity by decreasing cancer cell proliferation, adhesion to
and invasion of extracellular matrix, and metalloproteinase
release. However, these effects have been demonstrated mainly
in vitro.
Although there is no head-to-head comparison between intra-
venous (i.e. nitrogen-containing bisphosphonates) and oral adminis-
trations (mainly clodronate), the better bioavailability of the
former (bioavailability of oral bisphosphonates is ~1%), together
with potential gastrointestinal side effects, and the risk of insuffi-
cient compliance with the latter, support the use of intravenous
nitrogen-containing bisphosphonates in the treatment of breast
metastatic bone disease [3]. However, this treatment schedule
requires regular clinic visits, which can reduce treatment conven-
ience for some patients. In the setting of adjuvant therapy of breast
cancer with bisphosphonates [13], or of the long-term prevention
of bone loss, oral formulation would offer some advantage and
convenience, provided an equivalent efficacy with intravenous
administration and minimal side effects could be ensured.
Ibandronate is a newly approved nitrogen-containing bisphos-
phonate in the European Union, with both intravenous and oral
formulations. Its efficacy in preventing skeletal events resulting
from metastatic breast cancer have been demonstrated in
randomized double-blind, multicenter phase III trials, in which the
primary end point was the number of 12-week periods with new
skeletal events. The occurrence of vertebral or non-vertebral
fractures, radiotherapy or surgery to bone during such a period
was expressed as skeletal morbidity period rate. Compared with
placebo, intravenous ibandronate administered every 3–4 weeks
at a dose of 6 mg significantly reduced the skeletal morbidity
period rate by 40%, as assessed in a multivariate Poisson regres-
sion analysis [8]. The oral daily form of 50 mg reduced the risk of
new bone events by 39% and was apparently well tolerated, as
shown in this issue of Annals of Oncology by Tripathy et al. [14].
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Using a post hoc analysis of time to multiple skeletal events, the
equivalent efficacy of the two ibandronate formulations was
recently confirmed [15]. However, in contrast to other bisphos-
phonates, oral ibandronate did not appear to reduce vertebral or
non-vertebral fracture risk in this 96-week trial. Whether this lack
of effect on fracture risk is related to the type of patient investi-
gated, the kind of antitumor regimen administered or to the drug
itself, deserves further study. Thus, direct comparative trials with
identical end points are needed to compare the reductions in new
skeletal events with intravenous and oral formulations of ibandro-
nate, and with other bisphosphonates. The results of such studies
should help to determine the place of oral ibandronate in the
management of breast cancer patients.
René Rizzoli
Service of Bone Diseases, WHO Collaborating Center for
Osteoporosis Prevention, Department of Rehabilitation and
Geriatrics, University Hospital, Geneva, Switzerland
(E-mail: Rene.Rizzoli@medecine.unige.ch)
References
1. Fleisch H. Bisphosphonates in bone diseases: From the Laboratory to the
Patients. 2000. Academic Press: San Diego, London.
2. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;
19: 80–100.
3. Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical
Oncology guideline on the role of bisphosphonates in breast cancer. J Clin
Oncol 2000; 18: 1378–1391.
4. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of the role of
bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;
327: 469.
5. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of
skeletal complications of metastatic breast cancer with pamidronate. J
Clin Oncol 1998; 16: 2038–2044.
6. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skele-
tal morbidity in women with advanced breast cancer and lytic bone
lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17:
846–854.
7. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidro-
nate in the treatment of skeletal metastases in patients with breast cancer
or osteolytic lesions of multiple myeloma: a phase III, double-blind,
comparative trial. Cancer J 2001; 7: 377–387.
8. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces
the incidence of skeletal complications in patients with breast cancer and
bone metastases. Ann Oncol 2003; 14: 1399–1405.
9. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of
oral clodronate in patients with bone metastases from breast cancer. J Clin
Oncol 1993; 11: 59–65.
10. Hurst M, Noble S. Clodronate: a review of its use in breast cancer. Drugs
Aging 1999; 15: 143–167.
11. Rogers MJ, Frith JC, Luckman SP et al. Molecular mechanisms of action
of bisphosphonates. Bone 1999; 24 (Suppl): 73S–79S.
12. Rodan GA, Reszka AA. Bisphosphonates mechanism of action. Curr Mol
Med 2002; 2: 571–577.
13. Powles TJ, Paterson S, Kanis JA et al. Randomized, placebo-controlled
trial of clodronate in patients with primary operable breast cancer. J Clin
Oncol 2002; 20: 3219–3224.
14. Tripathy D, Lichinitser M, Lazarev A et al. Oral ibandronate for the treat-
ment of metastatic bone disease in breast cancer: efficacy and safety
results from a randomized, double-blind, placebo-controlled trial. Ann
Oncol 2004; 15: 743–750.
15. Tripathy D, Budde M. Assessing the efficacy of ibandronate for the
prevention of skeletal-related events in metastatic bone disease: a method-
ological comparison. Bone 2004; 34 (Suppl 1): S91.

